Correspondence to ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
We read with great interest the article by Singh and Cleveland, which the authors reported that the observed hypersensitivity reactions (HSRs) associated with allopurinol and febuxostat were not different.1 This conclusion differs from previous studies on HSRs associated with allopurinol and febuxos...
Saved in:
Published in | Annals of the rheumatic diseases Vol. 81; no. 6; p. e107 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
BMJ Publishing Group Ltd and European League Against Rheumatism
01.06.2022
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | We read with great interest the article by Singh and Cleveland, which the authors reported that the observed hypersensitivity reactions (HSRs) associated with allopurinol and febuxostat were not different.1 This conclusion differs from previous studies on HSRs associated with allopurinol and febuxostat using claimed data2 and intramural databases.3 The discrepancy may arise from different inclusion criteria for the diagnosis of HSRs based on International Classification of Diseases, Ninth Revision (ICD-9) coding system, methods for identifying causative drugs, methods for stratification, as well as ethnicity of the involved population. |
---|---|
Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Correspondence-2 content type line 14 ObjectType-Letter to the Editor-1 ObjectType-Correspondence-1 ObjectType-Commentary-2 content type line 23 |
ISSN: | 0003-4967 1468-2060 1468-2060 |
DOI: | 10.1136/annrheumdis-2020-218090 |